Results 231 to 240 of about 199,488 (284)
Critical illness and sex hormones: response and impact of the hypothalamic-pituitary-gonadal axis. [PDF]
Ma Y +6 more
europepmc +1 more source
Reply to “Extending the Interpretation of Biomarker Dynamics in SOD1‐ALS Proteomics”
Annals of Neurology, EarlyView.
Christina Steffke +2 more
wiley +1 more source
Heat stress disrupts gut microbial balance in poultry, impairing nutrient absorption and immunity. This review outlines the interplay between thermal stress and microbiome dynamics and discusses integrative mitigation strategies, probiotics, phytogenics, cooling systems, and genetic adaptation to enhance poultry resilience.
O. E. Oke +9 more
wiley +1 more source
Associations of caffeine and caffeine metabolites with sex hormones among 6-19-year-old children and adolescents. [PDF]
Li S, Yuan Z, Zhao Y, Wang N.
europepmc +1 more source
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih +3 more
wiley +1 more source
Urinary Glyphosate Concentrations and Serum Sex Hormones in a Nationally Representative U.S. Sample: NHANES 2017-2018. [PDF]
Wu WY, Wang DS, Lin HC, Wang C, Lin CY.
europepmc +1 more source
A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen +14 more
wiley +1 more source
Circulating Levels of Angiotensinogen, Sex Hormones, and Hormone Therapy-The Multi-Ethnic Study of Atherosclerosis (MESA). [PDF]
Lidani KCF +11 more
europepmc +1 more source
Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami +10 more
wiley +1 more source

